Cell-bound complement activation products associate with lupus severity in SLE

OBJECTIVES: To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4. METHODS: All subjects (n=495) fulfilled the American College of Rheumatology (ACR) classification criteria for SLE. Abnormal CB-CAPs (erythrocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Arriens, Cristina, Alexander, Roberta Vezza, Narain, Sonali, Saxena, Amit, Collins, Christopher E, Wallace, Daniel J, Massarotti, Elena, Conklin, John, Kalunian, Kenneth C, Putterman, Chaim, Ramsey-Goldman, Rosalind, Buyon, Jill P, Askanase, Anca, Furie, Richard A, James, Judith A, Bello, Ghalib A, Manzi, Susan, Ahearn, Joseph, O'Malley, Tyler, Weinstein, Arthur, Dervieux, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228655/
https://www.ncbi.nlm.nih.gov/pubmed/32371480
http://dx.doi.org/10.1136/lupus-2019-000377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228655/
https://www.ncbi.nlm.nih.gov/pubmed/32371480
http://dx.doi.org/10.1136/lupus-2019-000377

Ejemplares similares